MORF Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 107890 min ago

@ $37.26

Ausgestellt: 14 Feb 2024 @ 21:46

Rendite: -25.01%

Vorheriges Signal: Feb 14 - 20:06

Vorheriges Signal: Kaufen

Rendite: 0.38 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:54):

Stats
Tagesvolumen	148 653
Durchschnittsvolumen	498 550
Marktkapitalisierung	1.40B
EPS	$0 ( 2024-04-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.76
ATR14	$0.0400 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.64
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

Volumen Korrelation

Lang: -0.05 (neutral)

Kurz: -0.43 (neutral)

Signal:(39.233) Neutral

Morphic Holding Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Morphic Holding Inc Korrelation - Währung/Rohstoff

0.82
( strong )

0.83
( strong )

0.00
( neutral )

0.45
( neutral )

0.01
( neutral )

-0.19
( neutral )

Morphic Holding Inc Finanzdaten

Annual	2023
Umsatz:	$521 000
Bruttogewinn:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2023
Umsatz:	$521 000
Bruttogewinn:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2022
Umsatz:	$70.81M
Bruttogewinn:	$69.80M (98.58 %)
EPS:	$-1.550

FY	2021
Umsatz:	$19.79M
Bruttogewinn:	$19.79M (100.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.